Pyrazoloquinazolines: Synthetic strategies and bioactivities

European Journal of Medicinal Chemistry

Volumn 97, Issue 1, 2015, Pages 444-461

  Garg, Mansi ^a   Chauhan, Monika ^a   Singh, Pankaj Kumar ^a   Alex, Jimi Marin ^a   Kumar, Raj ^a  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

Author keywords

Biological activities; Docking; Pyrazoloquinazolines; QSAR; SAR; Synthetic strategies

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; AMPA RECEPTOR AGONIST; ANTIALLERGIC AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; DNA TOPOISOMERASE INHIBITOR; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; POLO LIKE KINASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE A; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRAZOLOQUINAZOLINE DERIVATIVE; PYRAZOLO[1,5 A ]QUINAZOLINE; PYRAZOLO[1,5 C ]QUINAZOLINE; PYRAZOLO[3,4 F ]QUINAZOLINE; PYRAZOLO[4,3 H ]QUINAZOLINE; PYRAZOLO[5,1 B ]QUINAZOLINE; PYRAZOLO[5,4 H ]QUINAZOLINE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; SYNTHESIS;

ANIMALS; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE; PYRAZOLES; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85047699120     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.11.051     Document Type: Review

References (112)

1. C. Beemelmanns, H.-U. Reissig, Samarium diiodide induced ketyl-(het) arene cyclisations towards novel N-heterocycles, Chem. Soc. Rev. 40 (2011) 2199-2210.
2. P. Jimenez, M. Roux, C. Turrion, F. Gomis, Thermochemical properties of Nheterocyclic compounds I. Enthalpies of combustion, vapour pressures and enthalpies of sublimation, and enthalpies of formation of pyrazole, imidazole, indazole, and benzimidazole, J. Chem. Thermodyn. 19 (1987) 985-992.
3. K. Shalini, P.K. Sharma, N. Kumar, Imidazole and its biological activities: a review, Chem. Sin. 1 (2010) 36-47.
4. C. Amit, A.S. Sheelmani, C. Payal, R. Dhawan, Chemistry of anticancer thiazole compounds, Chemistry 2 (2014).
5. B.T. Green, S.T. Lee, K.E. Panter, D.R. Brown, Piperidine alkaloids: human and food animal teratogens, Food Chem. Toxicol. 50 (2012) 2049-2055.
6. M. Nakamura, A. Bhatnagar, J. Sadoshima, Overview of pyridine nucleotides review series, Circ. Res. 111 (2012) 604-610.
7. A.D. Yamaguchi, D. Mandal, J. Yamaguchi, K. Itami, Oxidative CH/CH coupling of azine and indole/pyrrole nuclei: palladium catalysis and synthesis of Eudistomin U, Chem. Lett. 40 (2011) 555-557.
8. D.M. Barber, A. Duris, A.L. Thompson, H.J. Sanganee, D.J. Dixon, One-pot asymmetric nitro-mannich/hydroamination cascades for the synthesis of pyrrolidine derivatives: combining organocatalysis and gold catalysis, ACS Catal. 4 (2014) 634-638.
9. D.F. Taber, P.K. Tirunahari, Indole synthesis: a review and proposed classification, Tetrahedron 67 (2011) 7195-7210.
10. A.A.H.S. AL-Janabi, Potential activity of the purine compounds caffeine and aminophylline on bacteria, J. Glob. Infect. Dis. 3 (2011) 133.
11. O. Afzal, S. Kumar, M.R. Haider, M.R. Ali, R. Kumar, M. Jaggi, S. Bawa, A review on anticancer potential of bioactive heterocycle quinoline, Eur. J. Med. Chem. 97 (2015) 871-910, http://dx.doi.org/10.1016/j.ejmech.2014.07.044.
12. Z. Shi, D.C. Koester, M. Boultadakis-Arapinis, F. Glorius, Rh (III)-catalyzed synthesis of multisubstituted isoquinoline and pyridine N-oxides from oximes and diazo compounds, J. Am. Chem. Soc. 135 (2013) 12204-12207.
13. J.M. Alex, S. Singh, R. Kumar, 1-Acetyl-3, 5-diaryl-4, 5-dihydro (1H) pyrazoles: exhibiting anticancer activity through intracellular ROS scavenging and the mitochondria-dependent death pathway, Arch. Pharm. 347 (2014) 717-727.
14. R.R. Ranatunge, R.A. Earl, D.S. Garvey, 3-(2-Methoxytetrahydrofuran-2-yl) pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors, Bioorg. Med. Chem. 14 (2004) 6049-6052.
15. D.-X. Jiang, X.-L. Lu, S. Hu, X.-B. Zhang, H.-H. Xu, A new derivative of Fipronil: effect of adding a glycinyl group to the 5-amine of pyrazole on phloem mobility and insecticidal activity, Pestic. Biochem. Physiol. 95 (2009) 126-130.
16. M.A. Ismail, J. Lehmann, D.A.A. El Ella, A. Albohy, K.A. Abouzid, Lonazolac analogues: molecular modeling, synthesis, and in vivo anti-inflammatory activity, Med. Chem. Res. 18 (2009) 725-744.
17. A.M. Naik, S.D. Sawant, G.A. Kavishwar, S.G. Kavishwar, Novel process for the synthesis of Zaleplon, Int. J. ChemTech Res. 2 (2010).
18. K. Okamoto, B.T. Eger, Mechanism of inhibition of xanthine oxidoreductase by Allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol, Nucleos Nucleot Nucl. 27 (2008) 888-893.
19. R.E. Petroski, J.E. Pomeroy, R. Das, Indiplon is a high-affinity positive allosteric modulator with selectivity for a1 subunit-containing GABAA receptors, J. Pharmacol. Exp. Ther. 317 (2006) 369-377.
20. R. Ockaili, F. Salloum, J. Hawkins, Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits, Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H1263-H1269.
21. R. Lan, Q. Liu, P. Fan, S. Lin, Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists, J. Med. Chem. 42 (1999) 769-776.
22. X. Yang, Y. Jin, H. Liu, Easy and efficient one-pot synthesis of pyrazolo [1, 5-c] quinazolines under mild copper-catalyzed conditions, R. Soc. Chem. Adv. 2 (2012) 11061-11066.
23. A. Witt, J. Bergman, Recent developments in the field of quinazoline chemistry, Curr. Org. Chem. 7 (2003) 659-677.
24. P.Y. Wen, S.M. Chang, K. Lamborn, Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American brain tumor consortium trial 04-02, Neuro. Oncol. 16 (2014) 567-578.
25. B. Green, Prazosin in the treatment of PTSD, J. Psychiatr. Pract. 20 (2014) 253-259.
26. P. Ellis, N. Coakley, R. Feld, S. Kuruvilla, Y. Ung, Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib (Iressa® ), Erlotinib (Tarceva® ), Afatinib, Dacomitinib or Icotinib in the Treatment of Nonesmall-cell Lung cancer: a Clinical Practice Guideline, 2014.
27. C. George, Pyrazolopyrimidines, Lancet 358 (2001) 1623-1626.
28. M. Chauhan, R. Kumar, Medicinal attributes of pyrazolo [3, 4-d] pyrimidines: a review, Bioorg. Med. Chem. 21 (2013) 5657-5668.
29. H. Cerecetto, A. Gerpe, M. Gonzalez, V.J. Aran, C.O. de Ocariz, Pharmacological properties of indazole derivatives: recent developments, Mini Rev. Med. Chem. 5 (2005) 869-878.
30. J.D. Bonk, M.E. Danielson, J.F. Gerster, D.S. Hays, Pyrazolopyridines and analogs thereof, in: U. S. Patents., 2009.
31. A.W. Garofalo, J.J. Jagodinski, 5-(Arylsulfonyl)-pyrazolopiperidines, in: WO Patents, 2010.
32. J. Bilbro, M. Mart, N. Kyprianou, Therapeutic value of quinazoline-based compounds in prostate cancer, Anticancer Res. 33 (2013) 4695-4700.
33. M. Li, B.-X. Zhao, Progress of the synthesis of condensed pyrazole derivatives (from 2010 to mid-2013), Eur. J. Med. Chem. 85 (2014) 311-340.
34. H. Alkhathlan, M. Al-Saad, H. Al-Hazimi, K. Al-Farhan, A. Mousa, Quinazoline, pyrazolo [1, 5-c] quinazoline and spiro quinazoline dimers from the reaction of 2-minoacetophenone hydrazones with triphosgene, J. Chem. Res. Synop. (2002) 587-588.
35. F. Varano, D. Catarzi, V. Colotta, Synthesis and biological evaluation of a new set of pyrazolo [1, 5-c] quinazoline-2-carboxylates as novel excitatory amino acid antagonists, J. Med. Chem. 45 (2002) 1035-1044.
36. F. Varano, D. Catarzi, V. Colotta, 1-Substituted pyrazolo [1, 5-c] quinazolines as novel Gly/NMDA receptor antagonists: synthesis, biological evaluation, and molecular modeling study, Bioorg. Med. Chem. 13 (2005) 5536-5549.
37. S. Guo, J. Wang, X. Fan, X. Zhang, D. Guo, Synthesis of pyrazolo [1, 5-c] quinazoline derivatives through copper-catalyzed tandem reaction of 5-(2-bromoaryl)-1 H-pyrazoles with carbonyl compounds and aqueous ammonia, J. Org. Chem. 78 (2013) 3262-3270.
38. V. Colotta, D. Catarzi, F. Varano, G. Filacchioni, Synthesis and binding activity of some pyrazolo [1, 5-c] quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand, J. Med. Chem. 39 (1996) 2915-2921.
39. D. Kumar, R. Kumar, Microwave-assisted synthesis of pyrazolo [1, 5-c] quinazolines and their derivatives, Tetrahedron Lett. 55 (2014) 2679-2683.
40. S.S. Nikam, B.E. Kornberg, AMPA receptor antagonists, Curr. Med. Chem. 8 (2001) 155-170.
41. A. Chimirri, R. Gitto, M. Zappala, AMPA receptor antagonists, Expert Opin. Ther. Pat. 9 (1999) 557-570.
42. D. Catarzi, V. Colotta, F. Varano, Competitive Gly/NMDA receptor antagonists, Curr. Top. Med. Chem. 6 (2006) 809-821.
43. P.D. Leeson, R. Baker, R.W. Carling, N.R. Curtis, Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the Nmethyl-D-aspartate receptor, J. Med. Chem. 34 (1991) 1243-1252.
44. F. Varano, D. Catarzi, V. Colotta, Novel AMPA and kainate receptor antagonists containing the pyrazolo [1, 5-c] quinazoline ring system: synthesis and structure-activity relationships, Bioorg. Med. Chem. 16 (2008) 2617-2626.
45. M. Karobath, G. Sperk, Stimulation of benzodiazepine receptor binding by gamma-aminobutyric acid, Proc. Natl. Acad. Sci. 76 (1979) 1004-1006.
46. H.T. Mohler, T. Okada, Benzodiazepine receptor: demonstration in the central nervous system, Science 198 (1977) 849-851.
47. E. Sigel, A. Buhr, The benzodiazepine binding site of GABA receptors, Trends Pharmacol. Sci. 18 (1997) 425-429.
48. J.A. Siuciak, S.A. McCarthy, D.S. Chapin, Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background, Neuropharmacol 54 (2008) 417-427.
49. C.J. Schmidt, D.S. Chapin, J. Cianfrogna, Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia, J. Pharmacol. Exp. Ther. 325 (2008) 681-690.
50. B. Asproni, G. Murineddu, A. Pau, G.A. Pinna, Synthesis and SAR study of new phenylimidazole-pyrazolo [1, 5-c] quinazolines as potent phosphodiesterase 10A inhibitors, Bioorg. Med. Chem. 19 (2011) 642-649.
51. R.F. Bruns, J.W. Daly, S.H. Snyder, Adenosine receptor binding: structureactivity analysis generates extremely potent xanthine antagonists, Proc. Natl. Acad. Sci. 80 (1983) 2077-2080.
52. K.A. Jacobson, P.J. Van Galen, M. Williams, Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential, J. Med. Chem. 35 (1992) 407-422.
53. V.-P. Jaakola, M.T. Griffith, M.A. Hanson, V. Cherezov, E.Y. Chien, J.R. Lane, A.P. IJzerman, R.C. Stevens, The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist, Science 322 (2008) 1211-1217.
54. T. Kanda, S. Shiozaki, J. Shimada, F. Suzuki, J. Nakamura, KF17837: a novel selective adenosine A receptor antagonist with anticataleptic activity, Eur. J. Pharmacol. 256 (1994) 263-268.
55. D. Catarzi, V. Colotta, F. Varano, Pyrazolo [1, 5-c] quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structureeaffinity relationships and molecular modeling studies, Bioorg. Med. Chem. 21 (2013) 283-294.
56. Y.A. Ammar, S. Bondock, A.G. El-Sehmi, M.S. El Gaby, A.M. Fouda, H.K. Thabet, Facile and convenient synthesis of pyrimidine, 4H-3, 1-benzoxazin-4-one, pyrazolo[5, 1-b] quinazoline, pyrido [1, 2-a] quinazoline, and chromeno [30 , 40: 4, 5] pyrido [1, 2-a] quinazoline derivatives, Turk. J. Chem. 35 (2011) 893-903.
57. D.-S. Chen, M.-M. Zhang, Y.-L. Li, Y. Liu, X.-S. Wang, Copper (I)-catalyzed synthesis of 1-arylpyrazolo [5, 1-b] quinazolin-9 (1 H)-one via intramolecular alkyne hydroamination, Tetrahedron 70 (2014) 2889-2893.
58. Y.-J. Zhou, M.-M. Zhang, Iodine-catalyzed synthesis of 2-arylpyrazolo [5, 1-b] quinazolin-9 (3H)-one derivatives in ionic liquids via domino reaction, Tetrahedron 70 (2014) 3440-3446.
59. F. Zafra, D. Lindholm, E. Castren, Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes, J. Neurosci. 12 (1992) 4793-4799.
60. R. Yao, G.M. Cooper, Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor, Science 267 (1995) 2003-2006.
61. S.D. Lyman, L. James, T.V. Bos, P. de Vries, Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells, Cell 75 (1993) 1157-1167.
62. A. Ullrich, J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity, Cell 61 (1990) 203-212.
63. A. Colquhoun, G.M. Lawrance, I.L. Shamovsky, Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4, 9-dihydro-4-methyl-9-oxo-pyrazolo [5, 1-b] quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA, J. Pharmacol. Exp. Ther. 310 (2004) 505-511.
64. B. Singh, J.R. Nadkarni, R.A. Vishwakarma, S.B. Bharate, M. Nivsarkar, S. Anandjiwala, The hydroalcoholic extract of Cassia alata (Linn.) leaves and its major compound rhein exhibits antiallergic activity via mast cell stabilization and lipoxygenase inhibition, J. Ethnopharmacol. 141 (2012) 469-473.
65. J.D. Abbott, G. Ball, D. Boumpas, S.L. Bridges, W. Chatham, J. Curtis, C. Daniel, L.B. Hughes, A.H. Kao, C. Langford, Passive cutaneous anaphylaxis, Rheumatol. Immunol. Ther. (2004) 689, 689.
66. Z. Ovary, Passive cutaneous anaphylaxis in the mouse, J. Immunol. 81 (1958) 355-357.
67. T. Capiris, J.C. Sircar, 4, 9eDihydro-9-oxo-N-1H-tetrazol-5-yl-pyrazolo [5, 1-b]-quinazoline-2-carboxamides and antiallergic compositions and methods using them, in, Google Patents., 1981.
68. M. Caldarelli, M. Angiolini, T. Disingrini, D. Donati, Synthesis and SAR of new pyrazolo [4, 3-h] quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors, Bioorg. Med. Chem. Lett. 21 (2011) 4507-4511.
69. L. Garuti, M. Roberti, G. Bottegoni, Polo-like kinases inhibitors, Curr. Med. Chem. 19 (2012) 3937-3948.
70. K. Strebhardt, A. Ullrich, Targeting polo-like kinase 1 for cancer therapy, Nat. Rev. Cancer 6 (2006) 321-330.
71. I. Beria, D. Ballinari, J.A. Bertrand, D. Borghi, Identification of 4, 5-dihydro-1 H-pyrazolo [4, 3-h] quinazoline derivatives as a new class of orally and selective polo-like kinase 1 inhibitors, J. Med. Chem. 53 (2010) 3532-3551.
72. I. Beria, R.T. Bossi, M.G. Brasca, M. Caruso, NMS-P937, a 4, 5-dihydro-1Hpyrazolo [4, 3-h] quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor, Bioorg. Med. Chem. Lett. 21 (2011) 2969-2974.
73. R.D. Cramer, D.E. Patterson, J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988) 5959-5967.
74. G.E. Kellogg, S.F. Semus, D.J. Abraham, HINT: a new method of empirical hydrophobic field calculation for CoMFA, J. Comput. Aided Mol. Des. 5 (1991) 545-552.
75. G. Klebe, Comparative Molecular Similarity Indices Analysis: CoMSIA, in: 3D QSAR in Drug Design, Springer, 1998, pp. 87-104.
76. G. Klebe, U. Abraham, T. Mietzner, Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994) 4130-4146.
77. G. Klebe, U. Abraham, Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries, J. Comput. Aided Mol. Des. 13 (1999) 1-10.
78. S. Lu, H.-C. Liu, Y.-D. Chen, Combined pharmacophore modeling, docking, and 3D-QSAR studies of PLK1 inhibitors, Int. J. Mol. Sci. 12 (2011) 8713-8739.
79. X. Grana, E.P. Reddy, Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclindependent kinase inhibitors (CKIs), Oncogene 11 (1995) 211-219.
80. C.J. Sherr, J.M. Roberts, CDK inhibitors: positive and negative regulators of G1-phase progression, Genes. Dev. 13 (1999) 1501-1512.
81. M.G. Brasca, N. Amboldi, D. Ballinari, A. Cameron, Identification of N, 1, 4, 4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl) phenyl] amino}-4, 5-dihydro-1H-pyrazolo [4, 3-h] quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor, J. Med. Chem. 52 (2009) 5152-5163.
82. J.A. McCammon, Computer-aided molecular design, Science 238 (1987) 486-491.
83. R. Gani, B. Nielsen, A. Fredenslund, A group contribution approach to computer-aided molecular design, AlChE J. 37 (1991) 1318-1332.
84. J. Wang, Y.-D. Chen, H.-C. Liu, De novo design of quinazoline derivatives as CDK2 inhibitors: 3D-QSAR, molecular fragment replacement and Volsurf predictions, Mol. Simul. 37 (2011) 824-836.
85. Y. Ai, S.-T. Wang, P.-H. Sun, F.-J. Song, Molecular modeling studies of 4, 5-Dihydro-1H-pyrazolo [4, 3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking, Int. J. Mol. Sci. 11 (2010) 3705-3724.
86. P. Lan, W.-N. Chen, G.-K. Xiao, P.-H. Sun, W.-M. Chen, 3D-QSAR and docking studies on pyrazolo [4, 3-h] qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors, Bioorg. Med. Chem. Lett. 20 (2010) 6764-6772.
87. L.S. Chen, S. Redkar, P. Taverna, J.E. Cortes, V. Gandhi, Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia, Blood 118 (2011) 693-702.
88. F. Casuscelli, C. Piutti, A. Ermoli, D. Faiardi, Substituted pyrazolo-quinazoline derivatives as kinase inhibitors, in, Google Patents, 2013.
89. R. Colombo, M. Caldarelli, M. Mennecozzi, M.L. Giorgini, Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase, Cancer Res. 70 (2010) 10255-10264.
90. S. Kemmler, Mps1-dependent phosphorylation of the kinetochore protein Ndc80 is an intrinsic step in spindle checkpoint activation, in: Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-carola, University of Heidelberg, Germany, 2007, 1-120.
91. N.E. Sharpless, R.A. Depinho, The mighty mouse: genetically engineered mouse models in cancer drug development, Nat. Rev. Drug Discov. 5 (2006) 741-754.
92. F. Orvieto, D. Branca, C. Giomini, Identification of substituted pyrazolo [1, 5-a] quinazolin-5 (4 H)-one as potent poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors, Bioorg. Med. Chem. 19 (2009) 4196-4200.
93. A. Petrov, A. Kasatochkin, Synthesis of 6, 7, 8, 9-Tetrahydropyrazolo [1, 5-a] quinazolines containing a 5-phenylamine fragment, Russ. J. Org. Chem. 49 (2013) 1250-1252.
94. J.N. Low, J. Cobo, J. Quiroga, J. Portilla, C. Glidewell, 10-(4-Chlorophenyl)-7-methyl-5, 6-dihydrobenzo [h] pyrazolo [5, 1-b] quinazoline and 2-(4-chlorophenyl)-5-methyl-6, 7-dihydrobenzo [h] pyrazolo [1, 5-a] quinazoline: isomeric molecules linked into hydrogen-bonded dimers or-stacked chains, Acta Crystallogr. Sect. C Cryst. Struct. Commun. 60 (2004) o604-o607.
95. C. Wenthur, R. Morrison, J. Daniels, Synthesis and SAR of substituted pyrazolo [1, 5-a] quinazolines as dual mGlu2/mGlu3 NAMs, Bioorg. Med. Chem. Lett. 24 (2014).
96. F. Ferraguti, R. Shigemoto, Metabotropic glutamate receptors, Cell. Tissue. Res. 326 (2006) 483-504.
97. Y. Tanabe, M. Masu, T. Ishii, A family of metabotropic glutamate receptors, Neuron 8 (1992) 169-179.
98. J.-P. Pin, R. Duvoisin, The metabotropic glutamate receptors: structure and functions, Neuropharmacology 34 (1995) 1-26.
99. J. Stenvang, A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer, Breast Cancer Res. Treat. 138 (2013).
100. S. Taliani, I. Pugliesi, E. Barresi, Phenylpyrazolo [1, 5-a] quinazolin-5 (4 H)-one: a suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) Inhibitors, J. Med. Chem. 56 (2013) 7458-7462.
101. N. Tonkikh, K. Ryzhanova, M. Petrova, 4, 5-Dihydropyrazolo [3, 4-f] quinazolines, Chem. Heterocycl. Compd. 39 (2003) 651-653.
102. J. Debray, S. Bonte, O. Lozach, Catalyst-free synthesis of quinazolin-4-ones from (hetero) aryl-guanidines: application to the synthesis of pyrazolo [4, 3-f] quinazolin-9-ones, a new family of DYRK1A inhibitors, Molec. Divers 16 (2012) 659-667.
103. S. Himpel, W. Tegge, R. Frank, S. Leder, H.-G. Joost, W. Becker, Specificity determinants of substrate recognition by the protein kinase DYRK1A, J. Biol. Chem. 275 (2000) 2431-2438.
104. V. Fotaki, M. Dierssen, S. Alcantara, S. Martinez, Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice, Curr. Med. Chem. 22 (2002) 6636-6647.
105. H.J. Menegay, M.P. Myers, F.M. Moeslein, G.E. Landreth, Biochemical characterization and localization of the dual specificity kinase CLK1, J. Cell. Sci. 113 (2000) 3241-3253.
106. T. Kojima, T. Zama, K. Wada, H. Onogi, M. Hagiwara, Cloning of human PRP4 reveals interaction with Clk1, J. Biol. Chem. 276 (2001) 32247-32256.
107. L.-H. Tsai, I. Delalle, V.S. Caviness, p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5, Nature 371 (1994).
108. R.S. Jope, G.V. Johnson, The glamour and gloom of glycogen synthase kinase-3, Trends Biochem. Sci. 29 (2004) 95-102.
109. I. Strakova, A.Y. Strakov, M. Petrova, Pyrazolo [5, 4-h] quinazolines, Chem. Heterocycl. Compd. 36 (2000) 847-850.
110. B.R. Vogt, Pyrazolo (1, 5-c) quinazoline derivatives and related compounds, in: U. S. Patents, Google Patents, 1978.
111. G. Traquandi, M.G. Brasca, Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors, in: U. S. Patents, Application no. US2009124605 (A1).
112. M. Caruso, I. Beria, M.G. Brasca, R. Ferguson, H. Posteri, B. Valsasina, Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors, in, Google Patents, 2013.